HUTCHMED (LON:HCM) Stock Price Up 16.4% – Time to Buy?

HUTCHMED (China) Limited (LON:HCM) was up 16.4% on Thursday . The company traded as high as GBX 212 and last traded at GBX 209. 497,827 shares were traded during trading, an increase of 1,204% from the average session volume of 38,169 shares. The stock had previously closed at GBX 179.50.

HUTCHMED Stock Up 1.4%

The company has a market capitalization of £1.84 billion, a P/E ratio of 106.00 and a beta of 0.43. The company has a quick ratio of 2.97, a current ratio of 4.96 and a debt-to-equity ratio of 7.91. The firm has a fifty day simple moving average of GBX 177.57 and a 200-day simple moving average of GBX 189.91.

HUTCHMED Company Profile

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.

HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13).